Status:
COMPLETED
Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Lead Sponsor:
University of Colorado, Denver
Collaborating Sponsors:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions:
Polycystic Kidney, Autosomal Dominant
Eligibility:
All Genders
8-22 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether the medication pravastatin will ameliorate renal and cardiovascular disease over a 3-year period in children and young adults with autosomal dominant ...
Detailed Description
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease, affecting 1 in 400 to 1000 individuals and accounting for 4% of end-stage renal disease in the United...
Eligibility Criteria
Inclusion
- Age 8-22 years
- Autosomal dominant polycystic kidney disease
- Normal kidney function
Exclusion
- Abnormal kidney function
- Past allergic history to medications used in study
- Liver disease
- Muscle disease/dystrophy
- Pregnancy, planned pregnancy, or lactation within study period
- Inability to cooperate with or clinical contraindication for magnetic resonance imaging
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2012
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT00456365
Start Date
November 1 2006
End Date
October 1 2012
Last Update
March 9 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Colorado at Denver and Health Sciences Center
Denver, Colorado, United States, 80262